Key statistics
On Monday, argenx SE (ARGX:NSQ) closed at 551.22, 28.50% above the 52 week low of 428.97 set on Jul 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 559.81 |
---|---|
High | 562.34 |
Low | 510.06 |
Bid | 515.21 |
Offer | 660.00 |
Previous close | 560.14 |
Average volume | 478.31k |
---|---|
Shares outstanding | 61.06m |
Free float | 60.74m |
P/E (TTM) | 34.83 |
Market cap | 34.24bn USD |
EPS (TTM) | 16.08 USD |
Data delayed at least 15 minutes, as of Jun 30 2025 21:00 BST.
More ▼
- argenx Advances Clinical Development of ARGX-119 in Congenital Myasthenic Syndromes
- argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy
- argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren’s Disease
- argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
- argenx Announces Results of Annual General Meeting of Shareholders
- argenx Reports First Quarter 2025 Financial Results and Provides Business Update
- argenx to Present at BofA Securities 2025 Health Care Conference
- argenx to Report First Quarter 2025 Financial Results and Business Update on May 8, 2025
- argenx Announces Positive CHMP Opinion for VYVGART (efgartigimod alfa) Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- argenx Announces Annual General Meeting of Shareholders on May 27, 2025
More ▼